Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04603066 · ClinicalTrials.gov registry record · Phase 1
Tariquidar-ondansetron Combination in Neuropathic Pain
A Phase 1 study of Neuropathic Pain, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT04603066: Completed Phase 1 study of Neuropathic Pain, sponsored by Washington University School of Medicine.
NCT04603066 is a Phase 1 study of Neuropathic Pain that has completed, run by Washington University School of Medicine. The registered enrollment target is 24 participants, below the 100-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04603066, a Phase 1 study of Neuropathic Pain, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Prospective, randomized, double-blind, placebo controlled, cross-over proof of concept study. To determine the pharmacokinetics and tolerability of co-administration of 5-HT3R antagonist ondansetron with a P-glycoprotein inhibitor tariquidar, in patients with neuropathic pain.
Primary Outcome
AUCinf for Ondansetron concentration in plasma based on venous blood sampling for plasma concentrations of ondansetron obtained at 0, 15, 30, 60, 90, 120, 180, and 240 minutes from the beginning of ondansetron infusion.
Conditions Studied
Interventions
- DRUG Ondansetron 16 mg with Tariquidar
- DRUG Ondansetron 16 mg with Placebo
Study Locations (1)
Missouri
- Washington University School of Medicine/Barnes-Jewish Hospital - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-01-31 |
| Est. Completion | 2023-11-03 |
| Phase | Phase 1 |
What the finished NCT04603066 record still lists
NCT04603066 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 100-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Neuropathic Pain appearing as the primary indexed condition, and to 2 interventions - of which Ondansetron 16 mg with Tariquidar is the first listed.
NCT04603066 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT04603066 about?
NCT04603066 is a clinical study titled "Tariquidar-ondansetron Combination in Neuropathic Pain". Prospective, randomized, double-blind, placebo controlled, cross-over proof of concept study. To determine the pharmacokinetics and tolerability of co-administration of 5-HT3R antagonist ondansetron with a P-glycoprotein inhibitor tariquidar, in patients with neuropathic pain.
What is the current status of trial NCT04603066?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2021-01-31. Estimated completion is 2023-11-03.
What conditions does trial NCT04603066 study?
This clinical trial studies the following conditions: Neuropathic Pain.
What interventions are being tested in trial NCT04603066?
The interventions under investigation include: Ondansetron 16 mg with Tariquidar (DRUG), Ondansetron 16 mg with Placebo (DRUG).
Who is sponsoring clinical trial NCT04603066?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04603066 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuropathic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04603066's enrollment target sits among peer trials
24 29th of 35 higher than 7 of 35 other Neuropathic Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuropathic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of CBD/CBD-A Oral Extract on Resting-state EEG and Neuropathic Pain Symptoms After SCI
RECRUITING · Phase 1
-
Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury
RECRUITING · Phase 1
-
Effects of Smoked Marijuana on Neuropathic Pain
COMPLETED · Phase 1
-
Topical Naloxone to Diagnose Ocular Pain
COMPLETED · Phase 1
-
Virtual Reality (VR) Self-Hypnosis Software
RECRUITING · NA
-
Neuropathic Pain and Operant Conditioning of Cutaneous Reflexes After SCI
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI